Get the Stockscreener App
2.14
1.90%
0.04
After Hours:
2.14
Protalix BioTherapeutics Inc. stock is traded at $2.14, with a volume of 734.71K.
It is up +1.90% in the last 24 hours and down -1.83% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$2.10
Open:
$2.14
24h Volume:
734.71K
Relative Volume:
0.77
Market Cap:
$172.42M
Revenue:
$52.74M
Net Income/Loss:
$-6.60M
P/E Ratio:
-25.33
EPS:
-0.0845
Net Cash Flow:
$-13.63M
1W Performance:
+12.63%
1M Performance:
-1.83%
6M Performance:
+16.94%
1Y Performance:
+32.10%
1-Day Range:
$2.10
$2.16
1-Week Range:
$1.90
$2.16
52-Week Range:
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.14 | 169.20M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans - TipRanks
Protalix BioTherapeutics Advances Rare Disease Treatments with Elfabrio® and PRX-115, Achieves Key Regulatory and Pipeline Milestones - Minichart
Protalix BioTherapeutics (PLX) posts new May 2026 corporate presentation for investors - Stock Titan
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Protalix BioTherapeutics (PLX) Q1 2026 8-K: EPS Not Disclosed, R - GuruFocus
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone - MSN
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets - The Globe and Mail
PLX: Chiesi milestone received - MSN
PLX: Chiesi Milestone Received - Yahoo Finance
Protalix BioTherapeutics 1Q Rev $33.8M >PLX - Moomoo
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Sahm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Delivers 234% Revenue Growth in Q1 2026 - AlphaStreet
Protalix BioTherapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protalix BioTherapeutics, Inc. Q1 2026 Financial Results & SEC 10-Q Filing Overview - Minichart
Protalix BioTherapeutics Reports Q1 2026 Results: $18.3M Net Income, $25M Milestone From Chiesi, and Strong Guidance for 2026 - Minichart
Protalix BioTherapeutics Backs 2026 Rev $78M-$83M >PLX - Moomoo
Protalix BioTherapeutics (PLX) Reports Q1 Earnings with Strong R - GuruFocus
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises By Investing.com - Investing.com South Africa
PLX: $25M milestone drives strong Q1, with 2026 guidance reaffirmed and pipeline advancing - TradingView
Earnings call transcript: Protalix Q1 2026: Earnings beat expectations, stock rises - Investing.com
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call - Yahoo Finance
Protalix BioTherapeutics 1Q 2026: Revenue $33.75M, Net income $18.32M, EPS $0.22— 10-Q Summary - TradingView
Protalix Hits Profitability, Fuels Pipeline with Elfabrio Milestone - BriefGlance
Protalix (PLX) turns Q1 2026 profit as Elfabrio EU milestone boosts cash - Stock Titan
Protalix reports Q1 2026 net income $18.3M on $33.8M revenue, $25M Chiesi milestone - TradingView
Protalix: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Protalix BioTherapeutics Q1 EPS USD 0.23 - TradingView
Protalix BioTherapeutics 1Q EPS 22c >PLX - Moomoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - Barchart.com
Protalix BioTherapeutics Q1 earnings preview - MSN
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? - MSN
Earnings Preview: PLX to Report Financial Results Pre-market on May 13 - Moomoo
Protalix to discuss quarterly results and business update May 13 - Stock Titan
MSN Money - MSN
Protalix BioTherapeutics (PLX) sets 2026 director, pay and stock plan votes - Stock Titan
[ARS] Protalix BioTherapeutics, Inc. SEC Filing - Stock Titan
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan
PLX News | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix BioTherapeutics (NYSE:PLX) Stock Price Down 2.2%Here's Why - MarketBeat
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 - Quantisnow
Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX) - Seeking Alpha
Aug Chart Watch: Is Protalix BioTherapeutics Inc currently under institutional pressure2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Protalix (PLX) Stock entering maturity stage | Price at $2.26, Up 3.20%AD Line Divergence - Newser
Targets Report: What is Protalix BioTherapeutics Incs valuation compared to sectorIPO Watch & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PLX Technical Analysis & ETF Price Forecast - Intellectia AI
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):